APP and Alzheimer disease: This can be inferred from mouse primary hippocampal neuronal experiments, where RAC1 inhibition with compound NSC23766 leads to attenuated γ-secretase activity, resulting in a reduction in cellular amyloid precursor protein (APP) and subsequent β-amyloid plaque formation, a hallmark of Alzheimer’s disease (AD) (29).